FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...